Merck wins Supreme Court hearing in pivotal Fosamax pre-emption case

Merck
Merck & Co.'s Fosamax, at the center of liability lawsuits over fracture risks, was once one of the company's top sellers, but it brought in less than $250 million last year. (Merck)

Merck & Co. has another chance for a reprieve in its long-running fight against Fosamax liability lawsuits. After an appeals court revived hundreds of patient claims last year, the U.S. Supreme Court has decided to hear Merck’s bid to put them to rest again.

Merck argues that the FDA rebuffed its 2008 bid to update the osteoporosis drug's label to warn of a link to severe bone fractures, but decided to order a warning in October 2010, when Merck did so. Now, Merck shouldn’t be held liable for that lack of a warning, because the FDA’s labeling power shields it, the company says.

And the high court will now review that argument, in an important development for the drug industry.The question of FDA pre-emption has made its way through multiple courts in recent years, and Merck’s Supreme Court appeal could settle it. That, in turn, could affect product liability cases across pharma.

Free Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This webinar will discuss the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

The history in Merck’s case is similar to a few other legal battles. Back in 2014, a federal judge dismissed a set of Fosamax fracture claims, saying the FDA’s decisions pre-empt state-court claims from patients. An appeals court in New Jersey revived those lawsuits—about 500 of them—and ordered them to be tried before a jury, because the facts weren’t a question for a judge to decide.

RELATED: The top 15 pharma companies by 2017 revenue - Merck

In reviewing Merck’s request for a hearing, the high court asked the U.S. Solicitor General to weigh in, and in its amicus brief backing Merck, the office says exactly the opposite: that FDA pre-emption is a legal question for a judge, not a jury. The FDA’s decision to reject Merck’s proposed label change supported pre-emption because it “prevented [Merck] from modifying the relevant labeling before late 2010.” Thus, he added, the court of appeals made a mistake in rejecting Merck’s defense. A war of words followed between the respondents in the case—the patients making the failure-to-warn claims—and Merck, culminating in the Supreme Court’s Thursday decision to take up the case.

When the company petitioned the court to weigh in on the Fosamax case last December, it argued in part that resolving the pre-emption puzzle would be vital to public health. Legal experts see it as vital to liability cases across the pharma industry.

Merck’s attorneys noted in its petition that even when drug companies collaborate with the FDA and propose a label warning, “they remain on the hook based on a lay jury's psychoanalysis of why the agency had blocked compliance with state law." Such an approach is “untenable” and “of great importance,” they said, “as proliferating tort suits stifle innovation, raise drug costs, undercut the FDA's role and ultimately hurt public health."

Fosamax was once one of the company's top sellers, but it's faced generic competition since 2008; last year it brought in less than $250 million, down from more than $3 billion at its peak.

Suggested Articles

One year after its landmark Reduce-It CV outcomes trial, Amarin has new data showing its Vascepa may help halt the progress of arterial plaque.

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.

In its quest to become the dominant SGLT2 diabetes med for heart failure, Jardiance is touting DPP-4 inhibitor-topping data to support its case.